Clinical Trial Update: Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating intrathecal delivery of scAAV9/JeT-GAN for Giant Axonal Neuropathy. Status: active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Axonal Neuropathy

Drugs mentioned

• scAAV9/JeT-GAN

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Giant Axonal Neuropathy, Gene Transfer | Phase 1 | Status: ACTIVE_NOT_RECRUITING